BridgeBio Pharma, Inc.
infigratinib
achondroplasia
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on infigratinib for achondroplasia is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“U.S. launch anticipated in late 2026/early 2027”